Ether-Linked Antiviral Compounds for SARS-CoV-2 3C-Like Protease Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatments to inhibit SARS-CoV-2 replication and treat COVID-19, given the emergence of more aggressive L-type variants and the global spread of the virus, which utilizes the ACE2 receptor for human-to-human transmission.
Innovation Solution
Development of novel compounds that inhibit the SARS-CoV-2 3C-like protease to prevent viral replication, formulated into pharmaceutical compositions for treating COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If novel compounds are developed to inhibit SARS-CoV-2 3C-like protease, then viral replication is inhibited and COVID-19 treatment efficacy is improved, but the complexity of drug development and formulation increases
Solution Approach 1:
The patent segments the protease inhibitor molecule into distinct functional components including a P1' substituent (X), a P2 amino acid residue, and a P3 substituent (Y), allowing systematic optimization of each segment's contribution to protease binding affinity and selectivity. This modular approach enables methodical development of compounds with improved efficacy while managing development complexity through structured molecular design
Solution Approach 2:
The patent systematically varies chemical parameters including the identity of amino acid residues at specific positions (P1, P2, P3), the nature of substituents (X and Y groups), and molecular stereochemistry to optimize protease inhibition. By changing these chemical parameters in a controlled manner, the patent achieves improved viral replication inhibition while maintaining manageable development complexity through structured parameter optimization
2Reliability
If compounds with high protease inhibition activity are designed, then COVID-19 treatment effectiveness is improved, but the manufacturing complexity and cost increase
Solution Approach 1:
The inhibitor molecule is divided into synthetically accessible building blocks including standardized amino acid derivatives and modular substituent groups. This segmentation allows each component to be synthesized using established chemical methods, then assembled through relatively straightforward peptide coupling reactions, thereby maintaining manufacturing feasibility while achieving high protease inhibition activity
Solution Approach 2:
The patent employs commonly available amino acid building blocks and standard protective group chemistry that use well-established, cost-effective synthetic protocols. By relying on inexpensive, readily available reagents and conventional synthesis methods rather than requiring exotic or multi-step procedures, the patent achieves high inhibition activity while keeping manufacturing complexity and cost manageable
Data Source
AI summary
The invention relates to compounds of Formula Iand pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q′ and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.